The global bronchitis treatment market is anticipated to grow significantly at a CAGR of 4.7% over the forecast period (2022-2028). The UD FDA approvals to the drugs used in bronchities treatment is the prominent factors for the makret gorwth. For instance, in March 2022, the Food and Drugs Administration(FDA), has approved budesonide and formoterol furmarate dehydrate drug developed by Mylan Pharmaceuticalsan inhaled medication that is used for the treatment of asthma and chronic obstructive pulmonary diseases(COPD). The drug-device combination product helps in improving the quality of life and reduces the cost of treatment. Moreover, in February 2022, the US FDA approved Lupin Ltd’s generic form of Brovana used to treat bronchoconstriction in people who are suffered from COPD. Lupin’s generic has a similar active agent of brovana and is meant to use only by nebulization. Both brovana and Lupin Ltd. Generic are available in 2ml vials containing 15 mcg of the therapy.
Browse the full report description of “Global Bronchitis Treatment Market Size, Share & Trends Analysis Report By Drug (Antibiotics, Anti Inflammatory Drugs, Bronchodilators, Mucolytic) By Distribution Channel (Retail Pharmacies, and Online Pharmaceutical Stores) By End-User (Hospital, and Clinics) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/bronchitis-treatment-market
Moreover, in March 2021, Gala Therapeutics Inc., has received conditional investigation device exemption approval from the US FDA., of RheSolve. The RheSolve is designed to evaluate Gala’s RheOx Bronchial Rheoplasty System for chronic bronchitis.
Market Coverage
• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered- by drugs,by distribution channel, by end-user
• Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
• Competitive Landscape- Glaxo Smith Kelvin, Novartis International AG, Astra Zeneca., Bayer Ag., Sun Pharmaceutical Industries Ltd., Melinta Therapeutics LLC., Resbotic, Sanofi and others.
• Key questions addressed by the report
• What is the market growth rate?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Bronchitis Treatment Market– Segmentation
By Drug
By Distribution Channel
By End-User
Global Bronchitis Treatment Market – Segmentation by Region
North America
• US
• Canada
Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/bronchitis-treatment-market